Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine
Ma J, Hine P, Clough E, Fish D, Coughlin R, Beltz G, Shew M. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 1996, 14: 1366-1374. PMID: 9004447, DOI: 10.1016/s0264-410x(96)00045-x.Peer-Reviewed Original ResearchConceptsCanine Lyme disease vaccineLyme disease vaccineDisease vaccineGeometric mean antibody titersInjection site swellingMean antibody titersTypical clinical signsMonths postchallengeVaccination timeSecond vaccinationBorrelial antigensSpirochetal antigensAntibody titersProtective efficacyControl beaglesAdverse reactionsVaccinated dogsClinical signsImmunological memoryLocal reactionsAntibody productionNormal beaglesVaccinatesLyme diseaseOsp A